Anusch Peyman

Title: Anusch Peyman: Innovator in Atherosclerosis Treatment

Introduction

Anusch Peyman is a notable inventor based in Frankfurt am Main, Germany. He has made significant contributions to the field of medicine, particularly in the treatment of atherosclerosis. With a total of 2 patents to his name, his work focuses on innovative methods to combat this serious health condition.

Latest Patents

Peyman's latest patents include groundbreaking methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody. The first patent provides methods and compositions aimed at inhibiting atherosclerotic plaque formation in a subject. This involves selecting a subject who has, or is at risk of developing, atherosclerosis, and administering a pharmaceutical composition that includes a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody or an antigen-binding protein. The second patent similarly outlines methods for inhibiting atherosclerosis through the administration of a PCSK9 inhibitor, emphasizing the importance of targeted treatment in managing this condition.

Career Highlights

Throughout his career, Anusch Peyman has worked with prominent companies in the biotechnology sector, including Sanofi Biotechnology and Regeneron Pharmaceuticals, Inc. His experience in these organizations has allowed him to develop and refine his innovative approaches to treating atherosclerosis.

Collaborations

Peyman has collaborated with esteemed colleagues such as William J. Sasiela and Viktoria Gusarova. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Anusch Peyman's contributions to the field of atherosclerosis treatment through his innovative patents highlight his role as a significant inventor in the medical community. His work continues to pave the way for new therapeutic strategies aimed at improving patient outcomes.